United States Patent 6,748,947 (Breath-Actuated Dry Powder Inhaler De‑Agglomerator): Claim Scope, Validity/Design-Around Risk, and US Patent Landscape
US Patent 6,748,947 is an apparatus patent directed to a specific de-agglomeration structure for a breath-actuated dry powder inhaler (DPI). Its independent claim 1 is tightly structural: it claims a non-rotationally fixed vane assembly at the first end of a swirl chamber, with transverse inlet(s) and an outlet at the second end, configured so breath-induced low pressure at the outlet draws air through the inlet ports and powder supply port into the swirl chamber.
Because the claims are apparatus-limited and framed around the internal fluidic architecture of the de-agglomerator, the key enforcement and design-around variables are whether a competitor’s DPI uses (i) a swirl chamber with the recited axial geometry and inlet/outlet placement, (ii) non-rotationally fixed vanes with oblique vane surfaces, and (iii) an arrangement where the powder supply port and inlet port create the claimed flow path that entrains powder into the swirl chamber.
What does US Patent 6,748,947 claim cover in a breath‑actuated DPI de‑agglomerator?
Executive scope answer
The patent claims a de-agglomerator comprising a swirl chamber extending along a longitudinal axis, with:
- a powder supply port at a first end communicating with an inhaler’s dry powder delivery passageway,
- at least one inlet port in the inner wall near the first end, extending transverse to the axis and allowing air entry into the first end region,
- an outlet port at the second end communicating the swirl chamber to ambient,
- non-rotationally fixed vanes attached at the first end, extending radially outward, each vane having an oblique surface facing transversely to the axis,
- arranged such that breath-induced low pressure at the outlet causes air to flow into the swirl chamber through the powder supply port and inlet port.
Claim 1 claim chart style breakdown (structural limitations that matter)
A. DPI context and functional preamble
- “de-agglomerator for use with a breath-actuated dry powder inhaler”
- breath-actuated implies inlet air flow is driven by patient inhalation rather than an external fan.
B. Swirl chamber geometry
- “inner wall defining a swirl chamber extending along a longitudinal axis from a first end to a second end”
- “outlet port providing fluid communication between second end … and a region exterior”
C. Powder supply interface
- “dry powder supply port in the first end … providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber”
- “whereby a breath induced low pressure at the outlet port causes air flows into the swirl chamber through the dry powder supply port and the inlet port”
This ties the powder supply port into the air flow path into the swirl chamber, not only as a static feed.
D. Air inlet interface into the first end region
- “at least one inlet port in the inner wall … adjacent to the first end”
- inlet port extends “substantially transverse to the axis”
- “providing fluid communication between a region exterior … and the first end”
So air enters directly into the first end region through ports transverse to the axis.
E. Non-rotationally fixed vanes at first end
- “vanes non-rotationally fixedly attached to the first end”
- “extending at least in part radially outwardly from the axis”
- “each of the vanes having an oblique surface facing at least in part in a direction transverse to the axis”
This is the most distinctive element: the vanes are fixed (no rotor, no rotation actuation), and the oblique surfaces create swirl/secondary flows in the swirl chamber.
F. Functional result tied to structure
- Breath-induced low pressure at outlet causes air flows through the powder supply port and inlet port into the swirl chamber.
This function supports interpretation that the inlet/outlet and chamber configuration are arranged for entrainment of powder into the swirl chamber.
Which dependent claims narrow the architecture (and how they change infringement/design-around)?
Claim 2: four vanes with hub aligned to axis
- “four vanes extending from a hub aligned with the axis to the wall of the swirl chamber.”
Scope impact:
- A design with 3 vanes or 6 vanes avoids claim 2 but still could fall within claim 1 if the independent limitations are met.
Claim 3–4: decreasing cross-sectional areas along axis; monotonic decrease
- Claim 3: “cross-sectional areas arranged transverse to the axis, decreasing from the first end to the second end”
- Claim 4: “decrease monotonically”
Scope impact:
- Competitors using a constant-area chamber, step changes, or expansions would be outside claims 3–4 while potentially still infringing claim 1.
Claim 5: convex inner wall
- “inner wall … is convex.”
Scope impact:
- Flat or concave swirl chamber walls can avoid claim 5 while leaving claim 1 exposure.
Claim 6: powder supply port faces parallel to axis
- “dry powder supply port faces substantially parallel to the axis.”
Scope impact:
- If powder is introduced via a port oriented transverse/oblique relative to axis, it may avoid claim 6.
Claim 7: outlet port extends transverse to axis
- “outlet port extends substantially transverse to the axis.”
Scope impact:
- A longitudinal outlet port or coaxial exhaust arrangement may avoid claim 7.
Claim 8–9: generally circular cross-sectional areas; inlet ports substantially tangential; two diametrically opposed inlets
- Claim 8: circular areas coaxially arranged; inlet port tangential to circular cross-sectional areas.
- Claim 9: two diametrically opposed inlet ports.
Scope impact:
- These are strong narrowing features. If a competitor uses non-tangential inlet(s), or places more than two inlets not diametrically opposed, it avoids claims 8–9.
Claim 10: anti-static additive in vanes
- “vanes include an anti-static additive.”
Scope impact:
- If no anti-static additive is used in the vane material, claim 10 may not be met. Note this is a material/composition limitation within an apparatus claim.
Claim 11: assembly structure (cup-like base and cover defining port and vane attachment)
- “assembled from a cup-like base closed with a cover”
- base defines inner wall, second end, and outlet port
- cover defines first end, vanes and supply port
- inlet port defined by both base and cover
Scope impact:
- Mechanical assembly details are sometimes easier to design around. If a competitor uses a monolithic shell or different seam/cover architecture, claim 11 may not be met.
How broadly does claim 12 extend from the de‑agglomerator to the whole inhaler?
Claim 12: breath-actuated DPI including de‑agglomerator + powder reservoir + delivery passageway
Claim 12 depends from claim 1 and adds inhaler-level elements:
- “dry powder delivery passageway” between exterior region and the de‑agglomerator’s supply port,
- “dry powder reservoir for exposing a predetermined amount of dry powder to the dry powder delivery passageway,”
- “whereby an air flow through the dry powder delivery passageway and the dry powder supply port will entrain dry powder from the dry powder reservoir into the swirl chamber.”
Scope impact:
- Enforcement extends to devices that use the claimed de-agglomerator in a DPI architecture with a reservoir and passageway entraining powder.
Claim 13: venturi adjacent reservoir
- “dry powder delivery passageway includes a venturi adjacent the dry powder reservoir.”
Scope impact:
- Venturi is a narrower limitation. Many DPI designs use throat geometries, nozzles, or constrictions; claim 13 may not map perfectly to every “constriction” term used by competitors.
Claim 14: dry powder in reservoir (composition presence)
- “further including dry powder in the dry powder reservoir.”
Scope impact:
- Likely not a differentiator in litigation because an operating DPI must include powder. It mainly clarifies “device in use” or “device with contents.”
Claim 15: medicament adhered to a particulate carrier
- “dry powder comprises a medicament composition having at least one active agent medicament adhered to a particulate carrier.”
Scope impact:
- This is more of a formulation category limitation. It covers carrier-based DPIs (common in lactose carrier systems and other carrier composites). It may not cover solutions, lyophilized wafers, or carrier-free particles if the “adhered to a particulate carrier” requirement is not met.
What is the likely claim construction logic for enforcement (and where does risk concentrate)?
Key structural bottlenecks for infringement under claim 1
The independent claim 1 requires all of the following to be present:
- A swirl chamber with the recited first end/second end orientation and inner wall.
- A powder supply port located in the first end.
- At least one inlet port adjacent to the first end, in the inner wall, transverse to the axis, allowing entry from an exterior region.
- An outlet port tied to the second end.
- Non-rotationally fixed vanes attached at the first end, radially extending, with oblique surfaces facing transversely.
- The breath-induced low pressure at the outlet causing airflow through the powder supply port and inlet port into the swirl chamber.
“Non-rotationally fixedly attached” as a separation from rotating devices
If a competitor uses a rotating impeller, a fan, or a mechanically driven vortex generator, the “non-rotationally fixedly attached” limitation creates clearance. Conversely, fixed vanes (no rotational motion) are closer.
Oblique surface geometry is another high-sensitivity limitation
A vane that is purely radial, purely axial, or lacks an oblique surface facing transversely may be argued as outside the scope. In practice this becomes a geometry-and-manufacturing drawing question, not a functional question.
Tangential inlet ports and mono-decreasing cross sections mainly affect narrower dependents
Claims 8–9 and 3–4 are more specific. A competitor can still be exposed on claim 1 if they keep the core swirl chamber, transverse inlet(s), and fixed oblique vanes, even if they deviate on the funneling/area profile or exact tangentiality.
How does this patent fit into the US DPI patent landscape (device architecture vs formulation vs actuation)?
Apparatus-focused DPI de‑agglomeration patents cluster
US DPI prior art and competitive estates typically separate into three buckets:
- Airflow and de-agglomeration hardware (swirl chambers, vortex generators, impaction/deaggregation screens).
- Delivery and metering mechanics (reservoir systems, dose cups, venturi/nozzle throat geometries).
- Powder engineering (carrier-based formulations, particle size distributions, surface treatments, anti-static approaches).
6,748,947 is predominantly bucket (1) with some bucket (2) hook via claim 12 (delivery passageway and reservoir) and bucket (3) via claim 15 (carrier adhered drug particles; anti-static additives in vanes via claim 10).
Litigation-relevance pattern
In DPI device disputes, the hardest technical battle is usually proving structural equivalence (ports placement, vane configuration, chamber profiles). The most differentiating elements here are the fixed oblique vanes and the swirl chamber inlet/outlet topology near the first end.
What companies and drug products are most likely to be implicated by 6,748,947’s structure?
Without a verified Orange Book/NDA association record or prosecution history mapping in the provided prompt, identifying specific NDA products and assignees would be speculative. The safe, business-relevant approach is to classify likely implicated program types:
- Breath-actuated carrier-based DPIs that use internal de-agglomeration swirl chambers.
- Devices with fixed vane vortex generators rather than rotating components.
- Architectures where a dose reservoir feeds into a delivery passage that entrains powder into a chamber that generates swirl prior to particle separation.
This patent is more likely to intersect with product-design teams, DPI platform licensors, and device OEMs than with formulation-only generic applicants.
When does 6,748,947 lose exclusivity in the US, and what terms matter for freedom to operate?
The prompt does not provide the patent grant date, term adjustment, or expected expiry. Those inputs are required to compute exclusivity end-date with precision.
What generic entry risks exist for a DPI that uses similar de‑agglomeration hardware?
Scenario analysis for claim 1
A generic DPI product is at risk if it uses:
- an internal swirl chamber with the same port topology (powder supply port at first end + transverse inlet port(s) adjacent to the first end + outlet at second end),
- non-rotationally fixed oblique vanes at the first end extending radially outward.
Lower-risk deviations
- Changing vane count does not eliminate claim 1 exposure if the “vanes” feature is still present and structurally similar.
- Changing cross-sectional profile or wall curvature may avoid only dependent claims (3–5) while leaving independent claim 1 intact.
Higher-risk deviations
- Using rotating or mechanically actuated de-agglomerators likely reduces exposure because claim 1 requires non-rotationally fixed vanes.
- Eliminating the transverse inlet into the first end region (or moving inlet function upstream) may be a stronger design-around than changing chamber taper.
What formulation and method-of-use protections does this patent add?
Formulation
- Claim 15 is limited to a powder where active medicament is adhered to a particulate carrier.
This aligns with carrier-based DPI powders. Carrier-free particle systems are less clearly covered.
Method-of-use
There is no method-of-use claim in the provided text. The patent is apparatus-centered.
Can competitors design around by altering vanes, ports, or chamber geometry?
Design-around levers tied to claim language
- Vane geometry: removing oblique surfaces facing transversely; using blades with primarily axial/radial surfaces may avoid the vane limitation.
- Vane motion: using rotating components instead of “non-rotationally fixed” vanes may move outside claim 1.
- Inlet port topology: changing inlet direction so it is not “substantially transverse to the axis,” or relocating inlet ports away from “adjacent to the first end,” can avoid key limitations.
- Swirl chamber feed path: if airflow does not go “through the dry powder supply port and the inlet port” under breath-induced low pressure at outlet, the functional bottleneck may be argued.
Assembly design-around
- Changing from a “cup-like base and cover” architecture may avoid claim 11 without affecting claim 1.
Key Takeaways
- US 6,748,947 is a DPI hardware patent focused on a swirl chamber de-agglomerator with transverse inlet(s), a powder supply port at the first end, a second-end outlet, and non-rotationally fixed radially outward vanes with oblique transversely facing surfaces.
- Independent claim 1 is the enforcement anchor; dependent claims narrow further on vane count, chamber taper, wall convexity, port orientation, tangential inlet placement, and specific assembly structure.
- The most effective design-around themes are altering vane geometry/motion, changing inlet port direction/placement, or breaking the claimed airflow path logic tied to breath-induced low pressure at the outlet.
- Formulation coverage in the provided claims is limited to carrier-adhered medicament powder (claim 15) and anti-static additive in vanes (claim 10); there is no method-of-use claim in the provided claim set.
FAQs
1) What is the single most distinguishing feature in claim 1?
The combination of non-rotationally fixed vanes at the first end with oblique surfaces facing transversely, together with a swirl chamber having transverse inlet port(s) adjacent to the first end and a second-end outlet.
2) Does changing the number of vanes avoid infringement?
It may avoid dependent claim 2, but does not avoid claim 1 if the device still has non-rotationally fixed vanes with oblique transversely facing surfaces and the same port/chamber topology.
3) Are venturi and dose metering features required for claim 1?
No. Venturi appears in dependent claim 13 under claim 12. Claim 1 is limited to the de-agglomerator architecture.
4) Does the patent cover carrier-free powders?
Only claim 15, as provided, requires medicament adhered to a particulate carrier. Carrier-free systems are not clearly covered by that limitation.
5) Is the patent about method-of-use for therapy?
No method-of-use claim appears in the provided claims. The scope is apparatus, with inhaler-level structure in claim 12.
References (APA)
- United States Patent 6,748,947. (Claim text as provided in the prompt).
